DOCOMO to Exhibit at MWC Barcelona 2025, World's Largest Connectivity Exhibition
24.1.2025 06:01:00 CET | Business Wire | Press release
NTT DOCOMO, INC. announced today that it will exhibit at MWC Barcelona 2025, the world's largest connectivity exhibition, in Barcelona, Spain from March 3 to 6. DOCOMO and its parent NTT Group will showcase technologies and initiatives focused on the core themes of non-terrestrial networks (NTN) and aerospace, open radio access networks (Open RAN), and entertainment, aiming to promote international standardization and new business focused on next-generation communication technologies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250123714093/en/

NTT DOCOMO Booth at MWC Barcelona 2025 (Graphic: Business Wire)
DOCOMO is developing cutting-edge technologies and businesses under its brand slogan “Bridging Worlds for Wonder & Happiness.”
In the NTN and aerospace field, DOCOMO will highlight its latest initiatives under the NTT Group’s “NTT C89” space-business strategy, such as mobile-connectivity services using unmanned vehicles, or high-altitude platform stations (HAPS), that fly in the stratosphere for days or months, using relays to provide mobile connectivity in mountainous and remote areas, including at sea and in the sky.
For Open RAN, DOCOMO will showcase collaborations with global telecom operators, and also Open RAN services that leverage the strengths of various global partners, offered by OREX SAI, INC., a joint venture with NEC.
In the entertainment field, DOCOMO will display MiRZA® XR glasses by NTT QONOQ Devices, Inc., designed for diverse use cases including enterprise solutions, including a touch-and-try demonstration of the NTT XR Real Support solution for remote work enabled by XR glasses. A commercial prototype of AR glasses, which are scheduled to be released from this summer onwards, will also be on display (final specifications may vary).
Additionally, DOCOMO will showcase FEEL TECH®,an innovative technology that transforms how sensory information are shared, tailoring to the other person’s unique perception. Through a demonstration that conveys the emotions and sensations of characters alongside visuals and sound, visitors will have the opportunity to experience DOCOMO’s vision for the future of entertainment.
DOCOMO will also showcase the Virtual EXPO of Expo 2025 primarily developed by NTT QONOQ, INC. aiming for a service launch in April. This virtual site allows visitors to experience the NTT Pavilion using various devices.
DOCOMO’s booth at MWC Barcelona 2025 will be located at Stand 4E50 in Hall 4. During the exhibition, Mr. Sadayuki Abeta, Chief Open RAN Strategist at NTT DOCOMO and Chief Technology Officer at OREX SAI, will give a presentation on his company’s latest initiatives, case histories and future plans at the MWC Broadcast Stage 2025 in Hall 4 on Tuesday, March 4 from 16:15 to 16:45 (please see MWC Barcelona 2025 website to confirm final content and schedule).
About MWC Barcelona 2025
https://www.mwcbarcelona.com/
When:
March 3 to 6
08:30 to 19:00 (16:00 on last day)
Where:
Fira Gran Via
Av. Joan Carles I, 64
08908 L'Hospitalet de Llobregat
Barcelona, Spain
NTT C89 is pending trademark registration.
MiRZA® is a registered trademark of NTT QONOQ Devices, Inc. in Japan.
FEEL TECH® is a registered trademark of NTT DOCOMO, INC. in Japan
About NTT DOCOMO
NTT DOCOMO, Japan's leading mobile operator with over 89 million subscribers, is one of the global leaders in 3G, 4G and 5G mobile network technologies.
Under the slogan "Bridging Worlds for Wonder & Happiness," DOCOMO is actively collaborating with global partners to expand its business scope from mobile services to comprehensive solutions, aiming to deliver unsurpassed value and drive innovation in technology and communications, ultimately to support positive change and advancement in global society.
https://www.docomo.ne.jp/english/
View source version on businesswire.com: https://www.businesswire.com/news/home/20250123714093/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 08:00:00 CET | Press release
Clinical and preclinical presentations reflect the company’s ongoing exploration of peripheral neuropathic pain Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greates
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom